Pacira BioSciences, Inc. (PCRX)
收市後：
| 前收市價 | 26.81 |
| 開市 | 26.65 |
| 買盤 | 25.89 x 200 |
| 賣出價 | 25.98 x 100 |
| 今日波幅 | 25.78 - 26.77 |
| 52 週波幅 | 25.74 - 48.60 |
| 成交量 | |
| 平均成交量 | 504,087 |
| 市值 | 1.247B |
| Beta 值 (5 年，每月) | 0.75 |
| 市盈率 (最近 12 個月) | 29.10 |
| 每股盈利 (最近 12 個月) | 0.89 |
| 業績公佈日 | 2024年5月01日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 46.40 |
Insider MonkeyAggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts. To skip our analysis of the recent market activity, you can go directly to see the Aggressive Stock Portfolio: 5 Stocks Picked by Analysts. By definition, aggressive stocks are ones that offer higher returns than conservative and relatively […]
ZacksPacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
Insider Monkey11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
